In this article, we will discuss Trametinib and RVO. So, let’s get started.
Retinal Vein Occlusion (RVO)
Across clinical trials with Trametinib, the incidence of RVO was 0.2%. RVO may lead to macular edema, decreased visual function, neovascularization, and glaucoma.
Urgently (within 24 hours) perform ophthalmological evaluation for patient-reported loss of vision or other
visual disturbances. Permanently discontinue Trametinib in patients with documented RVO.